FAQ: Predictive Oncology's $344.4 Million Digital Asset Treasury Strategy with ATH Token

What is the main announcement from Predictive Oncology?

Predictive Oncology announced the pricing of two concurrent private placement transactions totaling approximately $344.4 million to support its new digital asset treasury strategy centered on ATH, the native token of the Aethir ecosystem.

How is the $344.4 million funding structured?

The funding consists of a $51.7 million cash PIPE and a $292.7 million crypto PIPE involving pre-funded warrants, with proceeds earmarked for ATH acquisition, working capital, and general corporate purposes.

What is Predictive Oncology’s core business focus?

Predictive Oncology specializes in using artificial intelligence and machine learning to expedite early drug discovery and enable drug development for cancer patients worldwide, with its scientifically validated AI platform PEDAL achieving 92% accuracy in predicting tumor response to drug compounds.

What specific digital asset will Predictive Oncology focus on in its treasury strategy?

The company will focus on accumulating ATH, the native utility token of the Aethir ecosystem, as part of its digital asset treasury strategy.

What resources does Predictive Oncology have for its drug discovery work?

The company has a vast biobank of more than 150,000 assay-capable heterogenous human tumor samples and a wholly owned CLIA laboratory facility, providing one of the industry’s broadest AI-based drug discovery solutions.

Where is Predictive Oncology headquartered?

The company is headquartered in Pittsburgh, PA.

Where can I find more information about Predictive Oncology?

For more information, visit the company’s website at https://predictive-oncology.com/.

What is the significance of this announcement for Predictive Oncology?

This represents a major strategic shift for the company, moving beyond its traditional cancer research focus to include a substantial digital asset treasury strategy while maintaining its core mission of AI-driven drug discovery.

How accurate is Predictive Oncology’s AI platform for drug discovery?

The company’s PEDAL AI platform can predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for more informed selection of drug/tumor type combinations.